Oncology Partnering Terms and Agreements -





The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology/cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in oncology partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Oncology partnering agreement structure
  • Oncology partnering contract documents
  • Top oncology deals by value
  • Most active oncology dealmakers

 

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains a comprehensive listing of all oncology partnering deals announced since 2009 including financial terms where available, including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in oncology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

                             

Chapter 3 provides a review of the leading oncology deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                                                                       

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all oncology partnering deals signed and announced since 2009 with a contract attached. The chapter is organized by oncology deal type, stage of development and technology type focus. Each deal title links via Weblink to an online version of the deal record with the contract document.

 

Chapter 7 provides a comprehensive directory of all oncology partnering deals signed and announced since 2009. The chapter is organized by specific oncology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all oncology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.

 

Report scope 

 

Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

 

Oncology Partnering Terms and Agreements includes:

 

  • Trends in oncology dealmaking in the biopharma industry since 2009
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life oncology deals
  • Access to over 3,500 oncology deals since 2009 and contract documents where available
  • The leading oncology deals by value since 2009
  • Most active oncology dealmakers since 2009
  • The leading oncology partnering resources

 

In Oncology Partnering Terms and Agreements, the available contracts are listed by:

 

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Oncology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 3,500 oncology deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise oncology rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


 

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in oncology dealmaking 

 

2.1. Introduction

2.2. Oncology partnering over the years

2.3. Big pharma oncology dealmaking activity

2.4. Big biotech oncology dealmaking activity

2.5. Most active in oncology partnering

2.6. Oncology partnering by deal type

2.7. Oncology partnering by industry sector

2.8. Oncology partnering by stage of development

2.9. Oncology partnering by technology type

2.10. Oncology partnering by oncology indication

2.11. Average deal terms for oncology

2.11.1 Oncology headline values

2.11.2 Oncology upfront payments

2.11.3 Oncology milestone payments

2.11.4 Oncology royalty rates

 

Chapter 3 – Leading oncology deals 

 

3.1. Introduction

3.2. Top oncology deals by value

 

Chapter 4 – Big pharma oncology deals 

 

4.1. Introduction

4.2. How to use big pharma partnering deals

4.3. Big pharma oncology partnering company profiles

 

Chapter 5 – Big biotech oncology deals 

 

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech oncology partnering company profiles

 

Chapter 6 – Oncology partnering contracts directory 

 

6.1. Introduction

 

6.2. By deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Licensing

Loan

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Termination

Warranty

 

6.3. By stage of development

 

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

 

6.4. By technology type

 

Adjuvant

Analysis

Antibodies

Assays

Biological compounds

Biomarkers

Biomaterials

Biosimilars/Bio-betters

Blood products

Cell culture

Clinical testing

Devices

Diagnostics

Discovery tools

Drug delivery

Enabling technology

Enviromental

Epigenetics

Equipment

Facilities

Gene therapy

Genomics

Implant

Industrial chemicals

In vitro models

Microarray

Nanotechnology

Oligonucleotide

Peptides

Personalised medicine

Pharmacogenomics

Processes

Proteomics

Radio/Chemo-therapy

Recombinant DNA

Research services

Research supplies

RNA therapeutics

Screening

Small molecules

Software tools

Vaccines

 

Chapter 7 – Oncology dealmaking by indication 

 

7.1. Introduction

7.2. Deals by therapeutic indication

Oncology

  • Symptoms
    • Oral mucositis
    • Cancer pain
      • Bone
      • Neuropathic
      • Muscular
       
    • Lymphoedema
    • Alopecia
    • Cachexia
    • Ulcers
    • Dysphagia
    • Tiredness
    • Weight loss
    • Nausea
    • Vomiting
    • Chemotherapy
    • Radiotherapy
     
  • Adenocarcinoma
  • Basal cell carcinoma
  • Bile duct cancer
  • Bladder cancer
  • Bone cancer
  • Brain cancer
  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Endometrial
  • Esophageal cancer
  • Gastric cancer
  • Head and neck cancer
  • Kaposi's sarcoma
  • Kidney cancer
  • Leukemia
    • Acute lymphoblastic leukemia
    • Acute myelogenous leukemia
    • Chronic lymphocytic leukemia
    • Chronic myelogenous leukemia
     
  • Liver cancer
  • Lung cancer
    • Small cell lung cancer
    • Non small cell lung cancer
     
  • Lymphoma
  • Hodgkin's lymphoma
  • Non Hodgkin's lymphoma
  • Melanoma
  • Mesothelioma
  • Metastases
    • Bone metastases
     
  • Multiple myeloma
  • Neuroblastoma
  • Non-melanoma skin cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cell carcinoma
  • Sarcoma
  • Solid tumors
  • Testicular cancer
  • Thyroid cancer

 

Chapter 8 – Partnering resource center 

 

8.1. Online partnering

8.2. Partnering events

8.3. Further reading on dealmaking

 

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Upgrades to subscription access products

Order Form – Therapy Reports

 

Appendices 

 

Appendix 1: Directory of oncology deals by Company A-Z 2009-2014

Appendix 2: Directory of oncology deals by stage of development 2009-2014

Appendix 3: Directory of oncology deals by deal type 2009-2014

Appendix 4: Directory of oncology deals by technology type 2009-2014

 

 Table of figures 

 

Figure 1: Oncology partnering since 2009

Figure 2: Big pharma – top 50 – Oncology deals 2009 to 2014

Figure 3: Big pharma oncology deal frequency – 2009 to 2014

Figure 4: Big biotech – top 50 – Oncology deals 2009 to 2014

Figure 5: Big biotech oncology deal frequency – 2009 to 2014

Figure 6: Active oncology dealmaking activity– 2009 to 2014

Figure 7: Oncology partnering by deal type since 2009

Figure 8: Oncology partnering by industry sector since 2009

Figure 9: Oncology partnering by stage of development since 2009

Figure 10: Oncology partnering by technology type since 2009

Figure 11: Oncology partnering by oncology target since 2009

Figure 12: Oncology deals with a headline value

Figure 13: Oncology deal headline value distribution, US$million – discovery stage

Figure 14: Oncology deal headline value distribution, US$million – preclinical stage

Figure 15: Oncology deal headline value distribution, US$million – phase I stage

Figure 16: Oncology deal headline value distribution, US$million – phase II stage

Figure 17: Oncology deal headline value distribution, US$million – phase III stage

Figure 18: Oncology deal headline value distribution, US$million – regulatory stage

Figure 19: Oncology deal headline value distribution, US$million – marketed stage

Figure 20: Summary median headline value by stage of development, 2009-2014

Figure 21 Oncology deals with upfront payment values

Figure 22: Oncology deal upfront payment distribution, US$million – discovery stage

Figure 23: Oncology deal upfront payment distribution, US$million – preclinical stage

Figure 24: Oncology deal upfront payment distribution, US$million – phase I stage

Figure 25: Oncology deal upfront payment distribution, US$million – phase II stage

Figure 26: Oncology deal upfront payment distribution, US$million – phase III stage

Figure 27: Oncology deal upfront payment distribution, US$million – regulatory stage

Figure 28: Oncology deal upfront payment distribution, US$million – marketed stage

Figure 29: Summary median upfront payments by stage of development, 2009-2014

Figure 30: Oncology deals with milestone payments

Figure 31: Oncology deal milestone distribution, US$million – discovery stage

Figure 32: Oncology deal milestone distribution, US$million – preclinical stage

Figure 33: Oncology deal milestone distribution, US$million – phase I stage

Figure 34: Oncology deal milestone distribution, US$million – phase II stage

Figure 35: Oncology deal milestone distribution, US$million – phase III stage

Figure 36: Oncology deal milestone distribution, US$million – regulatory stage

Figure 37: Oncology deal milestone distribution, US$million – marketed stage

Figure 38: Oncology deals with royalty rates, %

Figure 39: Oncology deal royalty rate distribution, US$million – discovery stage

Figure 40: Oncology deal royalty rate distribution, US$million – preclinical stage

Figure 41: Oncology deal royalty rate distribution, US$million – phase I stage

Figure 42: Oncology deal royalty rate distribution, US$million – phase II stage

Figure 43: Oncology deal royalty rate distribution, US$million – phase III stage

Figure 44: Oncology deal royalty rate distribution, US$million – regulatory stage

Figure 45: Summary median royalty rate by stage of development, 2009-2014

Figure 46: Top oncology deals by value since 2009